3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
pembrolizumab
302
Carboplatin
155
Nivolumab
154
Cisplatin
139
Cyclophosphamide
130
Paclitaxel
127
Magnetic Resonance Spectroscopy
98
Specimen Handling
95
Radiotherapy
90
Gemcitabine
87
Dexamethasone
83
Biopsy
81
Ipilimumab
78
Docetaxel
75
Doxorubicin
75
Rituximab
69
Etoposide
67
atezolizumab
61
durvalumab
60
Lenalidomide
59
Radiation
59
Pemetrexed
58
Taxes
57
Bevacizumab
54
Prednisone
54
fludarabine
54
olaparib
53
Cytarabine
49
Vincristine
49
Fluorouracil
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
olaratumab
×
1 year
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts